JP2008537482A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537482A5
JP2008537482A5 JP2008501054A JP2008501054A JP2008537482A5 JP 2008537482 A5 JP2008537482 A5 JP 2008537482A5 JP 2008501054 A JP2008501054 A JP 2008501054A JP 2008501054 A JP2008501054 A JP 2008501054A JP 2008537482 A5 JP2008537482 A5 JP 2008537482A5
Authority
JP
Japan
Prior art keywords
amino acid
protein
nucleic acid
virus
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008501054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/009010 external-priority patent/WO2006099360A2/en
Publication of JP2008537482A publication Critical patent/JP2008537482A/ja
Publication of JP2008537482A5 publication Critical patent/JP2008537482A5/ja
Pending legal-status Critical Current

Links

JP2008501054A 2005-03-10 2006-03-09 メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法 Pending JP2008537482A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66073505P 2005-03-10 2005-03-10
PCT/US2006/009010 WO2006099360A2 (en) 2005-03-10 2006-03-09 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus

Publications (2)

Publication Number Publication Date
JP2008537482A JP2008537482A (ja) 2008-09-18
JP2008537482A5 true JP2008537482A5 (https=) 2009-04-30

Family

ID=36992353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008501054A Pending JP2008537482A (ja) 2005-03-10 2006-03-09 メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法

Country Status (8)

Country Link
US (2) US20060216700A1 (https=)
EP (1) EP1869225A4 (https=)
JP (1) JP2008537482A (https=)
KR (1) KR20070110924A (https=)
CN (1) CN101548009A (https=)
AU (1) AU2006223138B2 (https=)
CA (1) CA2600484A1 (https=)
WO (1) WO2006099360A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
KR20040002853A (ko) 2001-01-19 2004-01-07 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
EP1485468A4 (en) 2002-02-21 2007-01-03 Medimmune Vaccines Inc RECOMBINANT PARAIN FLUENZAVIRUS EXPRESSION SYSTEMS AND VACCINES WITH ANTIGENS FROM METAPNEUMOVIRUS STEM-RELATED HETEROLOGISTS
US20080213749A1 (en) * 2007-03-02 2008-09-04 Melanie Feola Compositions and methods for detecting human metapneumovirus
US20090017517A1 (en) * 2007-07-13 2009-01-15 Medimmune, Llc Preparation of Negative-Stranded RNA Viruses by Electroporation
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
GB0809881D0 (en) * 2008-05-30 2008-07-09 Genomica Sau Method for detecting respiratory viral agents in a test sample
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
WO2017172890A1 (en) 2016-03-29 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
CN106282407A (zh) * 2016-08-11 2017-01-04 青岛易邦生物工程有限公司 一种b亚群禽肺病毒疫苗的效检方法
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
CN109628413A (zh) * 2018-12-29 2019-04-16 广东和信健康科技有限公司 一种人偏肺病毒的培养方法及其产物和应用
CN120022355A (zh) * 2023-11-22 2025-05-23 长春百克生物科技股份公司 一种mRNA疫苗及其应用
CN120866573A (zh) * 2025-06-26 2025-10-31 温氏食品集团股份有限公司 一种基于纳米孔测序的番鸭c型偏肺病毒全基因组测序方法
CN121086052A (zh) * 2025-09-04 2025-12-09 上海申锐联生物医药有限公司 一种棘球蚴Eg95蛋白、编码该蛋白的核苷酸及mRNA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US20020019891A1 (en) * 1999-12-30 2002-02-14 James Morrow Generic device controller unit and method
JP2002025374A (ja) 2000-07-07 2002-01-25 Matsushita Electric Ind Co Ltd Ｅｌシート及びこれを用いたスイッチ
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
KR20040002853A (ko) * 2001-01-19 2004-01-07 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
EP1485468A4 (en) * 2002-02-21 2007-01-03 Medimmune Vaccines Inc RECOMBINANT PARAIN FLUENZAVIRUS EXPRESSION SYSTEMS AND VACCINES WITH ANTIGENS FROM METAPNEUMOVIRUS STEM-RELATED HETEROLOGISTS
US20060216824A1 (en) * 2003-01-31 2006-09-28 Tsuyoshi Tokusumi Paramyxovirus vector encoding ribozyme and utilization thereof
US7704491B2 (en) * 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
EP1622574A4 (en) * 2003-04-25 2006-10-18 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)

Similar Documents

Publication Publication Date Title
JP2008537482A5 (https=)
Iwata-Yoshikawa et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection
Steward et al. RNA editing in Newcastle disease virus
St-Jean et al. Human respiratory coronavirus OC43: genetic stability and neuroinvasion
Meyer et al. Endogenous retroviruses: with us and against us
Stobart et al. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity
Moore et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2
Harris et al. Interaction of poliovirus polypeptide 3CDpro with the 5 ‘and 3 ‘termini of the poliovirus genome. Identification of viral and cellular cofactors needed for efficient binding.
Yamada et al. Proteolytic activation of the spike protein at a novel RRRR/S motif is implicated in furin-dependent entry, syncytium formation, and infectivity of coronavirus infectious bronchitis virus in cultured cells
Shiura et al. PEG10 viral aspartic protease domain is essential for the maintenance of fetal capillary structure in the mouse placenta
Ziebuhr et al. Human coronavirus 229E papain-like proteases have overlapping specificities but distinct functions in viral replication
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
JP2006149395A5 (https=)
Mangel et al. Specific interactions of the adenovirus proteinase with the viral DNA, an 11-amino-acid viral peptide, and the cellular protein actin
York et al. Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junin arenavirus envelope glycoprotein
Flügel et al. Proteolytic processing of foamy virus Gag and Pol proteins
GB2409274A (en) Trap-tagging: a novel method for the identification and purification of RNA-protein complexes
Chow et al. Adenovirus-mediated expression of the C-terminal domain of SARS-CoV spike protein is sufficient to induce apoptosis in Vero E6 cells
JP2008545393A5 (https=)
Barretto et al. Deubiquitinating activity of the SARS-CoV papain-like protease
Lu et al. Spike gene deletion quasispecies in serum of patient with acute MERS‐CoV infection
Woo et al. In silico analysis of ORF1ab in coronavirus HKU1 genome reveals a unique putative cleavage site of coronavirus HKU1 3C‐like protease
WO2006038129A3 (en) Hepatitis c virus replication system
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
Sohrab et al. In silico prediction and designing of potential siRNAs to be used as antivirals against SARS-CoV-2